California-based obesity-focused clinical-stage pharma Aardvark Therapeutics saw its shares tumble nearly 26% to $4.99, after it announced that the US Food and Drug Administration (FDA) has placed a ...

Swedish neuroscience specialist BioArctic (Nasdaq Stockholm: BIOA B) said partner Eisai expects Alzheimer’s disease therapy ...

Fasenra (benralizumab) has received US Food and Drug Administration (FDA) approval for the treatment of patients 12 years and older with hypereosinophilic syndrome (HES) without an identifiable ...

US biotech Regenxbio (Nasdaq: RGNX) announced top-line and interim functional data from the pivotal Phase III portion of the Phase I/II/III AFFINITY DUCHENNE trial of RGX-202, a potential ...

39-43 Putney High Street, Putney London, SW15 1SP United Kingdom ...

Arcera was established by ADQ, Abu Dhabi's sovereign investment holding company, as a purpose-built platform to consolidate global pharmaceutical manufacturing and commercial assets under one ...

A Boston-based biotechnology company developing next-generation CAR-T cell therapies for immuno-oncology, attracting major partnerships with Astellas and a landmark acquisition agreement with Eli ...

A China-based biotechnology company focused on developing innovative oncology and immuno-oncology therapies with multiple approved drugs and a robust pipeline targeting various cancer types. A ...

A clinical-stage oncology company headquartered in Cambridge, Massachusetts. The company operates as a U.S.-based R&D organization progressing peptide therapeutics into global clinical development ...

A clinical-stage biotechnology company based in the Boston, Massachusetts area. The company is developing targeted radiopharmaceuticals for solid tumors and runs clinical development through ...

An AI-native pharmaceutical company headquartered in New York City, with additional operational hubs across Boston, the San Francisco Bay Area, and North Carolina’s Research Triangle. The company ...